Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 1/2022

07.01.2022 | Clinical Investigation

Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI

verfasst von: Hiroshi Tamura, Yoko Akune, Yoshimune Hiratsuka, Ryo Kawasaki, Ai Kido, Masahiro Miyake, Rei Goto, Masakazu Yamada

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the effectiveness of screening and subsequent intervention for age-related macular degeneration (AMD) in Japan.

Study design

Best-case-scenario analysis using a Markov model.

Methods

The clinical effectiveness and cost-effectiveness of screening for AMD were assessed by calculating the reduction proportion of blindness and the incremental cost-effectiveness ratio (ICER). The Markov model simulation began at screening at the age of 40 years and ended at screening at the age of 90 years. The first-eye and second-eye combined model assumed annual state-transition probabilities in the development and treatment of AMD. Data on prevalence, morbidity, transition probability, utility value, and treatment costs were obtained from previously published reports. Sensitivity analysis was performed to assess the influence of the parameters.

Results

In the base-case analysis, screening for AMD every 5 years, beginning at age 40 years and ending at age 74 years (reflecting the screening ages of the current Japanese legal “Specific Health Checkups”) showed a decrease of 40.7% in the total number of blind patients. The screening program reduced the number of blind people more than did the additional AREDS/AREDS2 formula supplement intake. However, the ICER of screening versus no screening was ¥9,846,411/QALY, which was beyond what people were willing to pay (WTP) in Japan. Sensitivity analysis revealed that neither OCT nor AI improved the ICER, but the scenario in which the prevalence of smoking decreased by 30% improved the ICER (¥4,655,601/QALY) to the level under the WTP.

Conclusions

Ophthalmologic screening for AMD is highly effective in reducing blindness but is not cost-effective, as demonstrated by a Markov model based on real-world evidence from Japan.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995;36:182–91.PubMed Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. Invest Ophthalmol Vis Sci. 1995;36:182–91.PubMed
2.
Zurück zum Zitat Munoz B, West SK, Rubin GS, Schein OD, Quigley HA, Bressler SB, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation study. Arch Ophthalmol. 2000;118:819–25.PubMed Munoz B, West SK, Rubin GS, Schein OD, Quigley HA, Bressler SB, et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation study. Arch Ophthalmol. 2000;118:819–25.PubMed
3.
Zurück zum Zitat Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med. 1991;325:1412–7.PubMed Sommer A, Tielsch JM, Katz J, Quigley HA, Gottsch JD, Javitt JC, et al. Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med. 1991;325:1412–7.PubMed
4.
Zurück zum Zitat Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye study. Clin Experiment Ophthalmol. 2000;28:268–73.PubMed Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye study. Clin Experiment Ophthalmol. 2000;28:268–73.PubMed
5.
Zurück zum Zitat Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol. 2000;118:264–9.PubMed Weih LM, VanNewkirk MR, McCarty CA, Taylor HR. Age-specific causes of bilateral visual impairment. Arch Ophthalmol. 2000;118:264–9.PubMed
6.
Zurück zum Zitat Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63:26–33.PubMed Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63:26–33.PubMed
7.
Zurück zum Zitat Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606–17.PubMed Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358:2606–17.PubMed
9.
Zurück zum Zitat Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K. Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP study). Ophthalmology. 2016;123:1269–77.PubMed Bhisitkul RB, Desai SJ, Boyer DS, Sadda SR, Zhang K. Fellow eye comparisons for 7-year outcomes in ranibizumab-treated AMD subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP study). Ophthalmology. 2016;123:1269–77.PubMed
10.
Zurück zum Zitat Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Age-related macular degeneration Preferred Practice Pattern®. Ophthalmology. 2020;127:P1–65.PubMed Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Age-related macular degeneration Preferred Practice Pattern®. Ophthalmology. 2020;127:P1–65.PubMed
12.
Zurück zum Zitat Brynskov T, Munch IC, Larsen TM, Erngaard L, Sørensen TL. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol. 2020;98:132–8.PubMed Brynskov T, Munch IC, Larsen TM, Erngaard L, Sørensen TL. Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration. Acta Ophthalmol. 2020;98:132–8.PubMed
13.
Zurück zum Zitat Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–61.PubMed Maguire MG, Martin DF, Ying GS, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123:1751–61.PubMed
14.
Zurück zum Zitat Nishikawa K, Oishi A, Hata M, Miyake M, Ooto S, Yamashiro K, et al. Four-year outcome of aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Sci Rep. 2019;9:3620.PubMedPubMedCentral Nishikawa K, Oishi A, Hata M, Miyake M, Ooto S, Yamashiro K, et al. Four-year outcome of aflibercept for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Sci Rep. 2019;9:3620.PubMedPubMedCentral
15.
Zurück zum Zitat Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.PubMed Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.PubMed
17.
Zurück zum Zitat Brown GC, Brown MM, Rapuano S, Boyer D. Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration. Am J Ophthalmol. 2020;218:225–41.PubMed Brown GC, Brown MM, Rapuano S, Boyer D. Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration. Am J Ophthalmol. 2020;218:225–41.PubMed
18.
Zurück zum Zitat Carrasco J, Pietsch G-A, Nicolas M-P, Koerber C, Bennison C, Yoon J. Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies. Adv Ther. 2020;37:300–15.PubMed Carrasco J, Pietsch G-A, Nicolas M-P, Koerber C, Bennison C, Yoon J. Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies. Adv Ther. 2020;37:300–15.PubMed
19.
Zurück zum Zitat Chan CKW, Gangwani RA, McGhee SM, Lian J, Wong DSH. Cost-effectiveness of screening for intermediate age-related macular degeneration during diabetic retinopathy screening. Ophthalmology. 2015;122:2278–85.PubMed Chan CKW, Gangwani RA, McGhee SM, Lian J, Wong DSH. Cost-effectiveness of screening for intermediate age-related macular degeneration during diabetic retinopathy screening. Ophthalmology. 2015;122:2278–85.PubMed
21.
Zurück zum Zitat Khalid S, Akram MU, Hassan T, Jameel A, Khalil T. Automated segmentation and quantification of drusen in fundus and optical coherence tomography images for detection of ARMD. J Digit Imaging. 2018;31:464–76.PubMed Khalid S, Akram MU, Hassan T, Jameel A, Khalil T. Automated segmentation and quantification of drusen in fundus and optical coherence tomography images for detection of ARMD. J Digit Imaging. 2018;31:464–76.PubMed
22.
Zurück zum Zitat Venhuizen FG, van Ginneken B, van Asten F, van Grinsven MJ, Fauser S, Hoyng CB, et al. Automated staging of age-related macular degeneration using optical coherence tomography. Invest Ophthalmol Vis Sci. 2017;58:2318–28.PubMed Venhuizen FG, van Ginneken B, van Asten F, van Grinsven MJ, Fauser S, Hoyng CB, et al. Automated staging of age-related macular degeneration using optical coherence tomography. Invest Ophthalmol Vis Sci. 2017;58:2318–28.PubMed
23.
Zurück zum Zitat Peng Y, Dharssi S, Chen Q, Keenan TD, Agron E, Wong WT, et al. DeepSeeNet: a deep learning model for automated classification of patient-based age-related macular degeneration severity from color fundus photographs. Ophthalmology. 2019;126:565–75.PubMed Peng Y, Dharssi S, Chen Q, Keenan TD, Agron E, Wong WT, et al. DeepSeeNet: a deep learning model for automated classification of patient-based age-related macular degeneration severity from color fundus photographs. Ophthalmology. 2019;126:565–75.PubMed
25.
Zurück zum Zitat Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye. 2005;19:935–44.PubMed Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye. 2005;19:935–44.PubMed
26.
Zurück zum Zitat Sasaki M, Harada S, Kawasaki Y, Watanabe M, Ito H, Tanaka H, et al. Gender-specific association of early age-related macular degeneration with systemic and genetic factors in a Japanese population. Sci Rep. 2018;8:1–8. Sasaki M, Harada S, Kawasaki Y, Watanabe M, Ito H, Tanaka H, et al. Gender-specific association of early age-related macular degeneration with systemic and genetic factors in a Japanese population. Sci Rep. 2018;8:1–8.
27.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMed Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.PubMed
28.
Zurück zum Zitat Elshout M, Webers CA, van der Reis MI, de Jong-Hesse Y, Schouten JS. Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study. BMC Ophthalmol. 2017;17:120.PubMedPubMedCentral Elshout M, Webers CA, van der Reis MI, de Jong-Hesse Y, Schouten JS. Tracing the natural course of visual acuity and quality of life in neovascular age-related macular degeneration: a systematic review and quality of life study. BMC Ophthalmol. 2017;17:120.PubMedPubMedCentral
29.
Zurück zum Zitat Uyama M, Takahashi K, Ida N, Miyashiro M, Ando A, Takahashi A, et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. Br J Ophthalmol. 2000;84:1018–23.PubMedPubMedCentral Uyama M, Takahashi K, Ida N, Miyashiro M, Ando A, Takahashi A, et al. The second eye of Japanese patients with unilateral exudative age related macular degeneration. Br J Ophthalmol. 2000;84:1018–23.PubMedPubMedCentral
30.
Zurück zum Zitat Sasaki M, Kawasaki R, Uchida A, Koto T, Shinoda H, Tsubota K, et al. Early signs of exudative age-related macular degeneration in Asians. Optom Vis Sci. 2014;91:849–53.PubMedPubMedCentral Sasaki M, Kawasaki R, Uchida A, Koto T, Shinoda H, Tsubota K, et al. Early signs of exudative age-related macular degeneration in Asians. Optom Vis Sci. 2014;91:849–53.PubMedPubMedCentral
31.
Zurück zum Zitat Nakata I, Yamashiro K, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A, et al. Prevalence and characteristics of age-related macular degeneration in the Japanese population: the Nagahama study. Am J Ophthalmol. 2013;156:1002-9.e2.PubMed Nakata I, Yamashiro K, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A, et al. Prevalence and characteristics of age-related macular degeneration in the Japanese population: the Nagahama study. Am J Ophthalmol. 2013;156:1002-9.e2.PubMed
32.
Zurück zum Zitat Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population: the Hisayama study. Ophthalmology. 2009;116:2135–40.PubMed Yasuda M, Kiyohara Y, Hata Y, Arakawa S, Yonemoto K, Doi Y, et al. Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population: the Hisayama study. Ophthalmology. 2009;116:2135–40.PubMed
34.
Zurück zum Zitat Takahashi K, Ogura Y, Ishibashi T, Shiraga F, Yuzawa M. Treatment guidelines for age-related macular degeneration. Article in Japanese. Nippon Ganka Gakkai Zasshi. 2012;116:1150–5.PubMed Takahashi K, Ogura Y, Ishibashi T, Shiraga F, Yuzawa M. Treatment guidelines for age-related macular degeneration. Article in Japanese. Nippon Ganka Gakkai Zasshi. 2012;116:1150–5.PubMed
35.
Zurück zum Zitat Sasaki M, Shinoda H, Koto T, Uchida A, Tsubota K, Ozawa Y. Use of micronutrient supplement for preventing advanced age-related macular degeneration in Japan. Arch Ophthalmol. 2012;130:254–5.PubMed Sasaki M, Shinoda H, Koto T, Uchida A, Tsubota K, Ozawa Y. Use of micronutrient supplement for preventing advanced age-related macular degeneration in Japan. Arch Ophthalmol. 2012;130:254–5.PubMed
36.
Zurück zum Zitat Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–36.PubMedCentral Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001;119:1417–36.PubMedCentral
37.
Zurück zum Zitat Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27:787–94.PubMedPubMedCentral Ghasemi Falavarjani K, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye. 2013;27:787–94.PubMedPubMedCentral
38.
Zurück zum Zitat Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119:1609–14.PubMed Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam W-C. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology. 2012;119:1609–14.PubMed
39.
Zurück zum Zitat Holden BA, Fricke TR, Ho SM, Wong R, Schlenther G, Cronje S, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol. 2008;126:1731–9.PubMed Holden BA, Fricke TR, Ho SM, Wong R, Schlenther G, Cronje S, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol. 2008;126:1731–9.PubMed
42.
Zurück zum Zitat Yanagi Y, Ueta T, Obata R, Iriyama A, Fukuda T, Hashimoto H. Utility values in Japanese patients with exudative age-related macular degeneration. Jpn J Ophthalmol. 2011;55:35–8.PubMed Yanagi Y, Ueta T, Obata R, Iriyama A, Fukuda T, Hashimoto H. Utility values in Japanese patients with exudative age-related macular degeneration. Jpn J Ophthalmol. 2011;55:35–8.PubMed
43.
Zurück zum Zitat Varma R, Wu J, Chong K, Azen SP, Hays RD, Los Angeles Latino Eye Study Group. Impact of severity and bilaterality of visual impairment on health-related quality of life. Ophthalmology. 2006;113:1846–53.PubMed Varma R, Wu J, Chong K, Azen SP, Hays RD, Los Angeles Latino Eye Study Group. Impact of severity and bilaterality of visual impairment on health-related quality of life. Ophthalmology. 2006;113:1846–53.PubMed
46.
Zurück zum Zitat Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19:422–37.PubMed Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19:422–37.PubMed
48.
Zurück zum Zitat Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, et al. Ranibizumab treatment in treatment-naïve neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study. Retina. 2020;40:1673–85.PubMed Holz FG, Figueroa MS, Bandello F, Yang Y, Ohji M, Dai H, et al. Ranibizumab treatment in treatment-naïve neovascular age-related macular degeneration: results from LUMINOUS, a global real-world study. Retina. 2020;40:1673–85.PubMed
49.
Zurück zum Zitat Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–83.PubMed Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 2012;119:1175–83.PubMed
50.
Zurück zum Zitat Rim TH, Cheng CY, Kim DW, Kim SS, Wong TY. A nationwide cohort study of cigarette smoking and risk of neovascular age-related macular degeneration in East Asian men. Br J Ophthalmol. 2017;101:1367–73.PubMed Rim TH, Cheng CY, Kim DW, Kim SS, Wong TY. A nationwide cohort study of cigarette smoking and risk of neovascular age-related macular degeneration in East Asian men. Br J Ophthalmol. 2017;101:1367–73.PubMed
53.
Zurück zum Zitat Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209-13.e2.PubMed Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153:209-13.e2.PubMed
54.
Zurück zum Zitat Kawasaki R, Wang JJ, Ji GJ, Taylor B, Oizumi T, Daimon M, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology. 2008;115(1376–81):1381.e1-2. Kawasaki R, Wang JJ, Ji GJ, Taylor B, Oizumi T, Daimon M, et al. Prevalence and risk factors for age-related macular degeneration in an adult Japanese population: the Funagata study. Ophthalmology. 2008;115(1376–81):1381.e1-2.
55.
Zurück zum Zitat Obata R, Yanagi Y, Inoue T, Yasuda M, Oshima Y, Sawaguchi S, et al. Prevalence and factors associated with age-related macular degeneration in a southwestern island population of Japan: the Kumejima study. Br J Ophthalmol. 2018;102:1047–53.PubMed Obata R, Yanagi Y, Inoue T, Yasuda M, Oshima Y, Sawaguchi S, et al. Prevalence and factors associated with age-related macular degeneration in a southwestern island population of Japan: the Kumejima study. Br J Ophthalmol. 2018;102:1047–53.PubMed
58.
Zurück zum Zitat Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. N Engl J Med. 1997;337:1052–7.PubMed Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. N Engl J Med. 1997;337:1052–7.PubMed
59.
Zurück zum Zitat Hayashida K, Imanaka Y, Murakami G, Takahashi Y, Nagai M, Kuriyama S, et al. Difference in lifetime medical expenditures between male smokers and non-smokers. Health Policy. 2010;94:84–9.PubMed Hayashida K, Imanaka Y, Murakami G, Takahashi Y, Nagai M, Kuriyama S, et al. Difference in lifetime medical expenditures between male smokers and non-smokers. Health Policy. 2010;94:84–9.PubMed
Metadaten
Titel
Real-world effectiveness of screening programs for age-related macular degeneration: amended Japanese specific health checkups and augmented screening programs with OCT or AI
verfasst von
Hiroshi Tamura
Yoko Akune
Yoshimune Hiratsuka
Ryo Kawasaki
Ai Kido
Masahiro Miyake
Rei Goto
Masakazu Yamada
Publikationsdatum
07.01.2022
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 1/2022
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-021-00890-0

Weitere Artikel der Ausgabe 1/2022

Japanese Journal of Ophthalmology 1/2022 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.